Medline is the largest provider of medical-surgical products and supply chain solutions in the US... Show more
Medline Inc. stands as the largest provider of medical-surgical (med-surg) products and supply chain solutions in the U.S., generating over 90% of revenue domestically. Operating through two core segments—Medline Brand and Supply Chain Solutions—the company manufactures and distributes essential products like surgical trays, wound care, gloves, and diagnostics, while offering logistics optimization for third-party brands. Its scale enables competitive advantages in procurement, manufacturing efficiency, and distribution networks, serving hospitals, surgery centers, and post-acute facilities.
In the medical instruments and supplies industry, Medline benefits from a strong private-label brand penetration and supply chain moat, differentiating it from peers like Cardinal Health. Medium-term positioning hinges on innovation in product customization and technology integration, with recent launches like Pick Pack Pro enhancing fulfillment capabilities. International expansion remains a growth avenue, though domestic dominance provides stability amid competitive pressures.
The Q1 2026 earnings release on May 6 will be pivotal, offering insights into early-year execution against full-year guidance and potentially influencing analyst revisions. Consensus expects quarterly revenue of $7.16 billion and EPS of $0.29, setting the tone for FY2026.
A landmark partnership with Symbotic for AI robotics in warehouses marks the first such deployment in healthcare distribution, promising cost savings and scalability. This, alongside new technologies like Pick Pack Pro, could accelerate margin expansion and draw positive analyst attention.
Analyst sentiment remains bullish post-IPO, with 90% Buy ratings and price targets averaging $53.52 (high $60, low $40). Recent initiations from firms like William Blair highlight supply chain strength, with EPS forecasts of $1.48 for 2026. Upgrades could follow if guidance is met, enhancing investor confidence.
The medical instruments and supplies sector benefits from structural tailwinds like an aging U.S. population driving demand for med-surg consumables and post-acute care. However, reimbursement reforms under Medicare and Medicaid could pressure pricing, while inflation in raw materials impacts costs.
Macro sensitivities include interest rates, given Medline's debt load, which could elevate financing costs if rates remain elevated. Geopolitical tensions may disrupt global supply chains for gloves and PPE (personal protective equipment). Conversely, technology adoption trends, such as AI and automation, align with Medline's initiatives, positioning it favorably. Healthcare policy shifts, including potential expansions in outpatient care, support volume growth.
Tickeron’s Trend Prediction Engine is an AI-powered forecasting tool that helps traders identify whether a stock, ETF, or other asset may move bullish, bearish, or sideways over the next week or month. Designed to spot developing trends, evaluate possible breakouts or reversals, and explore predictions across a wide range of tradable instruments, it includes searchable prediction categories, historical context, and alert-oriented functionality. This resource empowers users to make informed decisions by leveraging advanced pattern recognition and probabilistic modeling. Explore the Trend Prediction Engine today for actionable insights on MDLN and beyond.
Medline's FY2026 outlook centers on 8-9% organic sales growth and Adjusted EBITDA of $3.5-3.6 billion, supported by analyst revenue estimates of $30.91 billion. Key themes include AI-driven supply chain efficiencies from the Symbotic partnership, potentially improving margins amid cost pressures. International revenue diversification and product innovation in surgical solutions and diagnostics will drive expansion.
Longer-term, watch margin sustainability through scale advantages, technology transitions like warehouse automation, and capital allocation post-IPO, including debt reduction or M&A (mergers and acquisitions). Competitive threats from integrated providers loom, but regulatory tailwinds in healthcare access could bolster demand. Consensus expectations, with EPS growth projected at 12.57% into 2027, underscore optimism if execution persists.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| TOCT | 26.95 | -0.06 | -0.22% |
| Innovator Equity DefinedPrtETF-2YTOc2027 | |||
| HELO | 67.70 | -0.18 | -0.27% |
| JPMorgan Hedged Equity Ldrd Ovrly ETF | |||
| THY | 21.84 | -0.10 | -0.46% |
| Toews Agility Dynamic Tactical Inc ETF | |||
| AVSD | 78.05 | -1.37 | -1.72% |
| Avantis Responsible International Eq ETF | |||
| NVTX | 90.30 | -9.63 | -9.64% |
| Tradr 2X Long NVTS Daily ETF | |||
MDLN saw its Momentum Indicator move below the 0 level on April 24, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 2 similar instances where the indicator turned negative. In of the 2 cases, the stock moved further down in the following days. The odds of a decline are at .
The Moving Average Convergence Divergence Histogram (MACD) for MDLN turned negative on April 24, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 2 similar instances when the indicator turned negative. In of the 2 cases the stock turned lower in the days that followed. This puts the odds of success at .
The RSI Indicator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MDLN advanced for three days, in of 21 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.714) is normal, around the industry mean (8.219). P/E Ratio (31.644) is within average values for comparable stocks, (108.484). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.206). Dividend Yield (0.000) settles around the average of (0.022) among similar stocks. P/S Ratio (1.050) is also within normal values, averaging (39.871).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. MDLN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MDLN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.